Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | FPR2 | P25090 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900321 | 1.00 | KMT2A (0.67) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL6350465 | 0.99 | KMT2A (0.66) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL7544578 | 0.94 | CTSS (0.61) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL3052482 | 0.91 | KMT2A (0.60) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL13291363 | 0.91 | KMT2A (0.64) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL27340724 | 0.91 | KMT2A (0.64) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL6165862 | 0.90 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL6165855 | 0.90 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL29165165 | 0.90 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL15545933 | 0.90 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | KMT2A 1942/4885MAPK1 2741/4885CTSS 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.